Clinuvel Pharmaceuticals Equity 2024

Clinuvel Pharmaceuticals Aktienanalyse

What does Clinuvel Pharmaceuticals do?

Clinuvel Pharmaceuticals Ltd is a biopharmaceutical company that specializes in researching, developing, and marketing drugs targeting skin pigmentation. The company was founded in 1987 and is headquartered in Melbourne, Australia. It has become a leading expert in the field of light and pigment medicine since its establishment. Clinuvel's business model focuses on utilizing innovative technologies and scientific research to develop new products and therapies that benefit patients worldwide. The company specializes in developing safe and effective drugs based on research in therapeutic areas such as skin pigment disorders and skin cancer prevention. In recent years, the company has expanded its various divisions to meet market demand and extend innovations to other areas of medicine. Clinuvel's main divisions are Pharmaceuticals and Nutraceuticals. Clinuvel's pharmaceutical division specializes in developing new drugs and therapies for modulating skin pigmentation. The company is particularly known for its flagship product, SCENESSE, an implant that allows people with the rare condition erythropoietic protoporphyria (EPP) to live without pain in the sun. SCENESSE has received European and Australian approvals and is prescribed worldwide by a growing network of treatment centers. Clinuvel's nutraceutical division focuses on developing dietary supplements and advising patients who want to improve their skin from within. This includes products like Cuvita, a dietary supplement containing antioxidants and other nutrients that can contribute to the health of hair, skin, and nails. Clinuvel has expanded its business models to meet the needs of patients in different regions of the world. For example, the company has developed a comprehensive integration strategy in Europe to promote research, development, and marketing of innovative products and therapies. Overall, Clinuvel Pharmaceuticals is a company that focuses on developing innovative drugs and therapies in the field of light and pigment medicine. It is known for its advanced research, successful development of SCENESSE, and commitment to patients worldwide. It will be interesting to see how the divisions develop in the future, but innovative drugs and therapies are definitely an important part of Clinuvel's future. Clinuvel Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Clinuvel Pharmaceuticals's Equity

Clinuvel Pharmaceuticals's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Clinuvel Pharmaceuticals's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Clinuvel Pharmaceuticals's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Clinuvel Pharmaceuticals's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Clinuvel Pharmaceuticals’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Clinuvel Pharmaceuticals stock

What is the equity of Clinuvel Pharmaceuticals this year?

Clinuvel Pharmaceuticals has equity of 203.01 M AUD this year.

What was the equity of Clinuvel Pharmaceuticals compared to the previous year?

The equity of Clinuvel Pharmaceuticals has increased/decreased by 61.69% increased compared to the previous year.

What impact does a high equity have on investors of Clinuvel Pharmaceuticals?

A high equity is advantageous for investors of Clinuvel Pharmaceuticals as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Clinuvel Pharmaceuticals?

A low equity can be a risk for investors of Clinuvel Pharmaceuticals, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Clinuvel Pharmaceuticals affect the company?

An increase in equity of Clinuvel Pharmaceuticals can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Clinuvel Pharmaceuticals affect the company?

A reduction in equity of Clinuvel Pharmaceuticals can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Clinuvel Pharmaceuticals?

Some factors that can affect the equity of Clinuvel Pharmaceuticals include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Clinuvel Pharmaceuticals so important for investors?

The equity of Clinuvel Pharmaceuticals is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Clinuvel Pharmaceuticals take to change the equity?

To change equity, Clinuvel Pharmaceuticals can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Clinuvel Pharmaceuticals pay?

Over the past 12 months, Clinuvel Pharmaceuticals paid a dividend of 0.07 AUD . This corresponds to a dividend yield of about 0.5 %. For the coming 12 months, Clinuvel Pharmaceuticals is expected to pay a dividend of 0.08 AUD.

What is the dividend yield of Clinuvel Pharmaceuticals?

The current dividend yield of Clinuvel Pharmaceuticals is 0.5 %.

When does Clinuvel Pharmaceuticals pay dividends?

Clinuvel Pharmaceuticals pays a quarterly dividend. This is distributed in the months of October, October, October, October.

How secure is the dividend of Clinuvel Pharmaceuticals?

Clinuvel Pharmaceuticals paid dividends every year for the past 13 years.

What is the dividend of Clinuvel Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0.08 AUD are expected. This corresponds to a dividend yield of 0.57 %.

In which sector is Clinuvel Pharmaceuticals located?

Clinuvel Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Clinuvel Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Clinuvel Pharmaceuticals from 9/20/2024 amounting to 0.071 AUD, you needed to have the stock in your portfolio before the ex-date on 9/5/2024.

When did Clinuvel Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/20/2024.

What was the dividend of Clinuvel Pharmaceuticals in the year 2023?

In the year 2023, Clinuvel Pharmaceuticals distributed 0.071 AUD as dividends.

In which currency does Clinuvel Pharmaceuticals pay out the dividend?

The dividends of Clinuvel Pharmaceuticals are distributed in AUD.